Apr 7, 2026
KITS Eyecare (KITS) sold off over 10% on its Q1 pre-release before ending the day down 3%, roughly equal to the top line miss versus guidance. Despite the shortfall, revenue grew 23% Y/Y…
… supported by over 60% growth in its more profitable glasses segment, which should continue to push EBITDA margins higher as its contribution increases.
With enough time, that could change how the market prices the story - shifting focus from growth to operating leverage.
About Bullpen: Bullpen Finance Inc. publishes content on Canadian markets and provides paid research coverage of select Canadian issuers. Bullpen is paid in cash by covered issuers, does not accept stock or options, does not hold positions in covered securities, and does not conduct investment banking business. Bullpen and LodeRock Advisors Inc. are affiliated; LodeRock provides investor relations services to issuers, some of whom are covered by Bullpen Research. When a post discusses a covered issuer, a specific disclosure appears at the top of the post. This post is published for general information purposes. It is not personalized investment advice and is not tailored to any individual reader’s circumstances. Bullpen is not a registered investment adviser or dealer. For full disclosures, including analyst certification, jurisdictional statements, and conflict of interest policies, please see our Legal & Disclosures section on our website.
